Trials / Completed
CompletedNCT00442832
TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection
A Phase 2, Randomized, Double Blind, Study of Intravenous TD 1792 Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- Theravance Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.
Detailed description
TD-1792 is compared to vancomycin for the treatment of cSSSI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-1792 | TD-1792 2 mg/kg/day IV |
| DRUG | Vancomycin | Vancomycin 1 Gm IV q 12 hrs |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2007-03-02
- Last updated
- 2021-01-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00442832. Inclusion in this directory is not an endorsement.